$0.20 Earnings Per Share Expected for Repligen Co. (RGEN) This Quarter

Share on StockTwits

Wall Street brokerages forecast that Repligen Co. (NASDAQ:RGEN) will announce earnings of $0.20 per share for the current quarter, according to Zacks. Five analysts have provided estimates for Repligen’s earnings, with the highest EPS estimate coming in at $0.21 and the lowest estimate coming in at $0.18. Repligen reported earnings per share of $0.17 during the same quarter last year, which suggests a positive year-over-year growth rate of 17.6%. The company is expected to report its next earnings results on Tuesday, May 14th.

On average, analysts expect that Repligen will report full-year earnings of $0.83 per share for the current year, with EPS estimates ranging from $0.81 to $0.84. For the next year, analysts expect that the firm will post earnings of $1.00 per share, with EPS estimates ranging from $0.97 to $1.05. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Repligen.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.21. The business had revenue of $51.90 million for the quarter, compared to the consensus estimate of $50.27 million. Repligen had a net margin of 8.56% and a return on equity of 5.51%. The company’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.20 EPS.

A number of research analysts have issued reports on RGEN shares. Zacks Investment Research raised shares of Repligen from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research report on Tuesday, December 25th. BidaskClub downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, ValuEngine downgraded shares of Repligen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $59.20.

In other Repligen news, CFO Jon Snodgres sold 1,875 shares of the company’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $58.88, for a total transaction of $110,400.00. Following the transaction, the chief financial officer now owns 26,821 shares in the company, valued at approximately $1,579,220.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anthony Hunt sold 14,550 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $59.63, for a total transaction of $867,616.50. Following the transaction, the chief executive officer now owns 219,616 shares in the company, valued at approximately $13,095,702.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,437 shares of company stock worth $2,855,032. Company insiders own 1.40% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Huntington National Bank purchased a new stake in Repligen during the 1st quarter valued at approximately $25,000. First Hawaiian Bank purchased a new stake in Repligen during the 4th quarter valued at approximately $28,000. Enlightenment Research LLC purchased a new stake in Repligen during the 4th quarter valued at approximately $42,000. Parallel Advisors LLC grew its holdings in Repligen by 485.1% during the 4th quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 1,043 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. grew its holdings in Repligen by 16.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 214 shares in the last quarter. 91.18% of the stock is owned by institutional investors.

Repligen stock traded down $1.52 during mid-day trading on Friday, reaching $53.80. 23,519 shares of the company traded hands, compared to its average volume of 265,042. The company has a market cap of $2.44 billion, a P/E ratio of 73.70, a PEG ratio of 3.83 and a beta of 1.08. Repligen has a 52-week low of $36.41 and a 52-week high of $70.50.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply